Alfuzosinof the Therapeutic Use of the Prolonged-Release Formulation Given Once Daily in the Management of Benign Prostatic Hyperplasia

[1]  R. Shanks,et al.  Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin , 2004, European Journal of Clinical Pharmacology.

[2]  P. V. Van Cangh,et al.  Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. , 2002, European urology.

[3]  C. Roehrborn,et al.  Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. , 2001, Urology.

[4]  C. Roehrborn,et al.  Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. , 2001, Urology.

[5]  N. Kyprianou,et al.  Future concepts in the medical therapy of benign prostatic hyperplasia , 2001, Current opinion in urology.

[6]  T. Paul,et al.  Bioequivalence study of a new once-a-day controlled-release alfuzosin formulation with the 5 mg twice daily formulation , 2000 .

[7]  G. Clifford,et al.  Medical Therapy for Benign Prostatic Hyperplasia: A Review of the Literature , 2000, European Urology.

[8]  P. V. van Kerrebroeck,et al.  Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic Hyperplasia , 2000, European Urology.

[9]  Noble,et al.  Subtype selective alpha1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia. , 1999, Expert opinion on investigational drugs.

[10]  Mcneill,et al.  Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled , 1999, BJU international.

[11]  M. Marberger,et al.  A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction , 1999, European Urology.

[12]  W. Trautwein,et al.  PROSTATE SELECTIVITY OF ALPHA 1 ADRENOCEPTOR BLOCKERS , 1999 .

[13]  K. Goa,et al.  Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. , 1999, Drugs.

[14]  P. Rosenzweig,et al.  Safety and pharmacokinetics of alfuzosin 10 mg once daily formulation comparatively to standard formulation (2.5 mg tid) in elderly subjects , 1999 .

[15]  F. Debruyne,et al.  Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia , 1998, European Urology.

[16]  D. Comet,et al.  Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice , 1998, Prostate Cancer and Prostatic Diseases.

[17]  I. Angel,et al.  Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. , 1998, Life sciences.

[18]  C. Chapple.  Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade. , 1998, British journal of urology.

[19]  X. Badia,et al.  Symptom Indices and Quality-of-Life Questionnaires for Use in Benign Prostatic Hyperplasia , 1997 .

[20]  E. Guillot,et al.  Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. , 1997, The Journal of pharmacology and experimental therapeutics.

[21]  T Tammela,et al.  Benign Prostatic Hyperplasia , 1997, Drugs & aging.

[22]  S. Roth,et al.  Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. , 1997, European urology.

[23]  P. Rigatti,et al.  Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. , 1997, European urology.

[24]  A. Leplège,et al.  Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. , 1996, Urology.

[25]  H. Mensink,et al.  Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. , 1996, Scandinavian journal of urology and nephrology.

[26]  H. Lepor,et al.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. , 1996, The New England journal of medicine.

[27]  A. Naylor,et al.  Evaluation of the pharmacological selectivity profile of α1 adrenoceptor antagonists at prostatic α1 adrenoceptors: binding, functional and in vivo studies , 1996 .

[28]  H. Bensadoun,et al.  Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey , 1994 .

[29]  A. Hatano,et al.  Pharmacological evidence of distinct oci‐adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery , 1994, British journal of pharmacology.

[30]  T. Branchek,et al.  The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. , 1994, Molecular pharmacology.

[31]  H. Mensink,et al.  ALFUZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - EFFECTS ON SYMPTOM SCORES, URINARY FLOW-RATES AND RESIDUAL VOLUME - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL , 1994 .

[32]  H. Bensadoun,et al.  Long‐term Treatment of Benign Prostatic Hyperplasia with Alfuzosin: a 12–18 Month Assessment , 1993 .

[33]  H. Lepor.  Medical therapy for benign prostatic hyperplasia. , 1993, Urology.

[34]  P. Manoury,et al.  Alfuzosin, a selective α1‐adrenoceptor antagonist in the lower urinary tract , 1993 .

[35]  A T Cockett,et al.  Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. , 1993, The Journal of urology.

[36]  D. McTavish,et al.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. , 1993, Drugs.

[37]  C. McCarthy,et al.  Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice. , 1993, European urology.

[38]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[39]  P. Teillac,et al.  Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group. , 1992, British journal of urology.

[40]  H. Bensadoun,et al.  Alfuzosin for treatment of benign prostatic hypertrophy , 1991, The Lancet.

[41]  K. Andersson,et al.  Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. , 1985, The Journal of urology.